6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          We report a case of a 38-year-old woman who was diagnosed with stage IV lung adenocarcinoma, harboring an epidermal growth factor receptor ( EGFR) L858R mutation on exon 21 and a T790 M mutation on exon 20. The patient was treated with osimertinib, a third-generation EGFR tyrosine kinase inhibitor ( EGFR-TKI) following treatment with nivolumab, an anti-Programmed Cell Death 1 (anti-PD1) antibody. After initiating osimertinib treatment, the patient began to complain of low-grade fever and shortness of breath without hypoxemia, and her chest radiograph and a CT scan revealed a remarkable antitumor response, although faint infiltrations were observed in the bilateral lung field. Bronchoalveolar lavage fluid mainly contained lymphocytes (CD4+/CD8+ ratio of 0.3), and a transbronchial lung biopsy specimen showed lymphocytic alveolitis with partial organization in several alveolar spaces. Therefore we diagnosed the patient with osimertinib-induced interstitial lung disease (ILD) after treatment with anti-PD1 antibody. We considered anti-PD1 therapies may be the risk factor of EGFR-TKI-induced ILD.

          Related collections

          Most cited references3

          • Record: found
          • Abstract: not found
          • Article: not found

          Consensus statement for the diagnosis and treatment of drug-induced lung injuries.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial.

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results

                Bookmark

                Author and article information

                Contributors
                +81-55-989-5230 , h.kenmotsu@scchr.jp
                Journal
                Invest New Drugs
                Invest New Drugs
                Investigational New Drugs
                Springer US (New York )
                0167-6997
                1573-0646
                6 September 2016
                6 September 2016
                2017
                : 35
                : 1
                : 105-107
                Affiliations
                [1 ]ISNI 0000 0004 1774 9501, GRID grid.415797.9, Division of Thoracic Oncology, , Shizuoka Cancer Center Hospital, ; 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777 Japan
                [2 ]ISNI 0000 0004 0377 8408, GRID grid.415466.4, Department of Pulmonary Medicine, , Seirei Hamamatsu General Hospital, ; Shizuoka, Japan
                [3 ]ISNI 0000 0004 1774 9501, GRID grid.415797.9, Division of Pathology, , Shizuoka Cancer Center Hospital, ; Shizuoka, Japan
                [4 ]ISNI 0000 0004 1774 9501, GRID grid.415797.9, Division of Diagnostic Radiology, , Shizuoka Cancer Center Hospital, ; Shizuoka, Japan
                Article
                389
                10.1007/s10637-016-0389-9
                5306260
                27599705
                1119a096-9da5-4be9-9c8e-323075392f7a
                © The Author(s) 2016

                Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 9 August 2016
                : 31 August 2016
                Categories
                Short Report
                Custom metadata
                © Springer Science+Business Media New York 2017

                Pharmacology & Pharmaceutical medicine
                lung cancer,egfr mutation,egfr tyrosine kinase inhibitor,anti-pd1 antibody,interstitial lung disease

                Comments

                Comment on this article